Coronary microvascular function, myocardial metabolism, and energetics in hypertrophic cardiomyopathy: Insights from positron emission tomography

European Heart Journal Cardiovascular Imaging

Volumn 14, Issue 2, 2013, Pages 95-101

  Timmer, Stefan A J ^a   Knaapen, Paul ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

HCM; Microvascular dysfunction; Myocardial metabolism; Myocardial perfusion; PET

Indexed keywords

AEROBIC METABOLISM; CAPILLARY DENSITY; CARDIAC IMAGING; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DILATATION; CORONARY ARTERY OBSTRUCTION; DIASTOLIC DYSFUNCTION; DISEASE SEVERITY; ENERGY TRANSFER; HEART DEATH; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART MUSCLE BLOOD FLOW; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE PERFUSION; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; MICROVASCULATURE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CARDIOMYOPATHY, HYPERTROPHIC; CORONARY CIRCULATION; ENERGY METABOLISM; FEMALE; HEART FUNCTION TESTS; HUMANS; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; OXYGEN CONSUMPTION; PHYSICAL ENDURANCE; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84872435664     PISSN: 20472404     EISSN: None     Source Type: Journal    
DOI: 10.1093/ehjci/jes242     Document Type: Review

References (54)

1. Ho CY. Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy. Circulation 2010;122:2430-40Y discussion 2440.
2. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287: 1308-20.
3. O'Gara PT, Bonow RO, Maron BJ et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation 1987;76:1214-23.
4. Jung WI, Sieverding L, Breuer J et al. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1998;97:2536-42.
5. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003;349:1027-35.
6. Timmer SAJ, Germans T, Gotte MJW et al. Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy. Eur J Nucl Med Mol Imaging 2010;37:779-88.
7. Ishiwata S, Maruno H, Senda M, Toyama H, Nishiyama S, Seki A. Mechanical efficiency in hypertrophic cardiomyopathy assessed by positron emission tomography with carbon 11 acetate. Am Heart J 1997;133:497-503.
8. Tadamura E, Tamaki N, Matsumori A et al. Myocardial metabolic changes in hypertrophic cardiomyopathy. J Nucl Med 1996;37:572-7.
9. Tadamura E, Kudoh T, Hattori N et al. Impairment of BMIPP uptake precedes abnormalities in oxygen and glucose metabolism in hypertrophic cardiomyopathy. J Nucl Med 1998;39:390-6.
10. Knaapen P, Germans T, Knuuti J et al. Myocardial energetics and efficiency: current status of the noninvasive approach. Circulation 2007;115:918-27.
11. Kim IS, Izawa H, Sobue T et al. Prognostic value of mechanical efficiency in ambulatory patients with idiopathic dilated cardiomyopathy in sinus rhythm. J Am Coll Cardiol 2002;39:1264-8.
12. Abozguia K, Elliott P, McKennaWet al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 2010;122:1562-9.
13. Timmer SAJ, Knaapen P, Germans T et al. Effects of alcohol septal ablation on coronary microvascular function and myocardial energetics in hypertrophic obstructive cardiomyopathy. Am J Physiol Heart Circ Physiol 2011;301:H129-37.
14. Iida H, Kanno I, Takahashi A et al. Measurement of absolute myocardial blood flow with H215O and dynamic positron-emission tomography. Strategy for quantification in relation to the partial-volume effect. Circulation 1988;78: 104-15.
15. Nitzsche EU, Choi Y, Czernin J, Hoh CK, Huang SC, Schelbert HR. Noninvasive quantification of myocardial blood flow in humans. A direct comparison of the [13N]ammonia and the [15O]water techniques. Circulation 1996;93:2000-6.
16. Kaufmann PA, Camici PG. Myocardial blood flow measurement by PET: technical aspects and clinical applications. J Nucl Med 2005;46:75-88.
17. Timmer SAJ, Germans T, Go? tte MJW et al. Relation of coronary microvascular dysfunction in hypertrophic cardiomyopathy to contractile dysfunction independent from myocardial injury. Am J Cardiol 2011;107:1522-8.
18. Knaapen P, van Dockum WG, Go? tte MJW et al. Regional heterogeneity of resting perfusion in hypertrophic cardiomyopathy is related to delayed contrast enhancement but not to systolic function: a PET and MRI study. J Nucl Cardiol 2006;13: 660-7.
19. Cannon RO, Rosing DR, Maron BJ et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation 1985;71:234-43.
20. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. JAC 1993;22:796-804.
21. Camici P, Chiriatti G, Lorenzoni R et al. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol 1991;17:879-86.
22. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ('small vessel') coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;8: 545-57.
23. Schwartzkopff B, Frenzel H, Dieckerhoff J et al. Morphometric investigation of human myocardium in arterial hypertension and valvular aortic stenosis. Eur Heart J 1992;13 (Suppl D):17-23.
24. Tanaka M, Fujiwara H, Onodera T et al. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation 1987;75:1130-9.
25. Knaapen P, Germans T, Camici PG et al. Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 2008;294:H986-93.
26. Buxton DB, Nienaber CA, Luxen A et al. Noninvasive quantitation of regional myocardial oxygen consumption in vivo with [1-11C]acetate and dynamic positron emission tomography. Circulation 1989;79:134-42.
27. Armbrecht JJ, Buxton DB, Brunken RC, Phelps ME, Schelbert HR. Regional myocardial oxygen consumption determined noninvasively in humans with [1-11C]acetate and dynamic positron tomography. Circulation 1989;80:863-72.
28. Sun KT, Yeatman LA, Buxton DB et al. Simultaneous measurement of myocardial oxygen consumption and blood flow using [1-carbon-11]acetate. J Nucl Med 1998; 39:272-80.
29. Tuunanen H, Kuusisto J, Toikka J et al. Myocardial perfusion, oxidative metabolism, and free fatty acid uptake in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene: a positron emission tomography study. J Nucl Cardiol 2007;14:354-65.
30. van Dockum WG, Kuijer JPA, Go? tte MJW et al. Septal ablation in hypertrophic obstructive cardiomyopathy improves systolic myocardial function in the lateral (free) wall: a follow-up study using CMR tissue tagging and 3D strain analysis. Eur Heart J 2006;27:2833-9.
31. Timmer SAJ, Knaapen P, Germans T et al. Right ventricular energetics in patients with hypertrophic cardiomyopathy and the effect of alcohol septal ablation. J Card Fail 2011;17:827-31.
32. Stolen KQ, Kemppainen J, Kalliokoski KK et al. Myocardial perfusion reserve and oxidative metabolism contribute to exercise capacity in patients with dilated cardiomyopathy. J Card Fail 2004;10:132-40.
33. Laine H, Katoh C, Luotolahti M et al. Myocardial oxygen consumption is unchanged but efficiency is reduced in patients with essential hypertension and left ventricular hypertrophy. Circulation 1999;100:2425-30.
34. Crilley JG, Boehm EA, Blair E et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003;41:1776-82.
35. Barnes E, Hall RJ, Dutka DP, Camici PG. Absolute blood flow and oxygen consumption in stunned myocardium in patients with coronary artery disease. J Am Coll Cardiol 2002;39:420-7.
36. Tuunanen H, Engblom E, Naum A et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 2006;114: 2130-37.
37. Neglia D, De Caterina A, Marraccini P et al. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2007;293:H3270-H8.
38. Olivotto I, Cecchi F, Gistri R et al. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol 2006;47:1043-8.
39. Petersen SE, Jerosch-Herold M, Hudsmith LE et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 2007;115:2418-2425.
40. Timmer SAJ, Germans T, Brouwer WP et al. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction. Eur J Heart Fail 2011.
41. Germans T, Ru?ssel IK, Go? tte MJW et al. How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010;12:13.
42. Ashrafian H, Redwood C, Blair E, Watkins H. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet 2003;19:263-8.
43. Beanlands RS, Nahmias C, Gordon E et al. The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: A double-blind, placebo-controlled, positron-emission tomography study. Circulation 2000;102:2070-5.
44. Nelson GS, Berger RD, Fetics BJ et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation 2000;102:3053-9.
45. Jorg-Ciopor M, Namdar M, Turina J et al. Regional myocardial ischemia in hypertrophic cardiomyopathy: impact of myectomy. J Thorac Cardiovasc Surg 2004;128: 163-9.
46. Cannon RO, McIntosh CL, Schenke WH, Maron BJ, Bonow RO, Epstein SE. Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy. Circulation 1989;79:766-75.
47. Cannon RO, Dilsizian V, O'Gara PT et al. Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy. Circulation 1992;85:1039-45.
48. Fananapazir L, Cannon RO, Tripodi D, Panza JA. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy. Circulation 1992;85:2149-61.
49. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-4.
50. Posma JL, Blanksma PK, van der Wall EE, Vaalburg W, Crijns HJ, Lie KI. Effects of permanent dual chamber pacing on myocardial perfusion in symptomatic hypertrophic cardiomyopathy. Heart 1996;76:358-62.
51. Udelson JE, Bonow RO, O'Gara PT et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1989;79:1052-60.
52. Choudhury L, Elliott P, Rimoldi O et al. Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy and effect of treatment. Basic Res Cardiol 1999;94:49-59.
53. Rajappan K, Rimoldi OE, Camici PG, Bellenger NG, Pennell DJ, Sheridan DJ. Functional changes in coronary microcirculation after valve replacement in patients with aortic stenosis. Circulation 2003;107:3170-5.
54. Neglia D, Fommei E, Varela-Carver A et al. Perindopril and indapamide reverse coronary microvascular remodelling and improve flow in arterial hypertension. J Hypertens 2011;29:364-72.